000274050 001__ 274050
000274050 005__ 20250119000259.0
000274050 0247_ $$2doi$$a10.1111/ene.16581
000274050 0247_ $$2pmid$$apmid:39714176
000274050 0247_ $$2pmc$$apmc:PMC11664725
000274050 0247_ $$2ISSN$$a1351-5101
000274050 0247_ $$2ISSN$$a1468-1331
000274050 0247_ $$2altmetric$$aaltmetric:172348960
000274050 037__ $$aDZNE-2025-00031
000274050 041__ $$aEnglish
000274050 082__ $$a610
000274050 1001_ $$00000-0003-1328-3620$$aBarba, Lorenzo$$b0
000274050 245__ $$aPrognostic serum biomarkers of synaptic, neuronal and glial injury in patients with acute ischemic stroke of the anterior circulation.
000274050 260__ $$aOxford [u.a.]$$bWiley-Blackwell$$c2025
000274050 3367_ $$2DRIVER$$aarticle
000274050 3367_ $$2DataCite$$aOutput Types/Journal article
000274050 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1736940440_5558
000274050 3367_ $$2BibTeX$$aARTICLE
000274050 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000274050 3367_ $$00$$2EndNote$$aJournal Article
000274050 520__ $$aWe aimed to investigate the prognostic role of β-synuclein in comparison to that of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) for predicting functional outcome after acute ischemic stroke (AIS).We measured serum concentrations of β-synuclein, NfL and GFAP 24 h after hospital admission in 213 consecutive patients with moderate-to-severe AIS. We investigated the association between serum biomarkers and radiological/clinical characteristics, 3-months mortality and functional outcome on the modified Rankin Scale (mRS).In 213 patients with AIS [mean age: 76.1 (±12.5) years, 53.1% males, median NIHSS score on admission: 13 (IQR: 9-17)], higher levels of β-synuclein, NfL and GFAP were associated with higher NIHSS scores and with lower Alberta Stroke Program CT Score (ASPECTS) points on admission. Serum β-synuclein levels was significantly correlated with NfL (rho = 0.715, p < 0.001) and GFAP concentrations (rho = 0.684, p < 0.001). The inclusion of serum β-synuclein significantly improved the accuracy of prediction models without biomarkers for overall mortality (AUC: 0.836 vs. 0.752, p < 0.001) and mRS 3-6 vs. 0-2 (AUC: 0.812 vs. 0.624, p < 0.001). Combination models with NfL and/or GFAP showed a similar accuracy.Serum β-synuclein may be used to assess synaptic damage/dysfunction and to predict 3-months clinical outcomes in patients with AIS.
000274050 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000274050 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000274050 650_7 $$2Other$$aGFAP
000274050 650_7 $$2Other$$aNfL
000274050 650_7 $$2Other$$abeta‐synuclein
000274050 650_7 $$2Other$$abiomarkers
000274050 650_7 $$2Other$$astroke
000274050 650_7 $$2NLM Chemicals$$aBiomarkers
000274050 650_7 $$2NLM Chemicals$$aGlial Fibrillary Acidic Protein
000274050 650_7 $$2NLM Chemicals$$aneurofilament protein L
000274050 650_7 $$2NLM Chemicals$$aNeurofilament Proteins
000274050 650_7 $$2NLM Chemicals$$aGFAP protein, human
000274050 650_2 $$2MeSH$$aHumans
000274050 650_2 $$2MeSH$$aMale
000274050 650_2 $$2MeSH$$aFemale
000274050 650_2 $$2MeSH$$aAged
000274050 650_2 $$2MeSH$$aBiomarkers: blood
000274050 650_2 $$2MeSH$$aIschemic Stroke: blood
000274050 650_2 $$2MeSH$$aIschemic Stroke: mortality
000274050 650_2 $$2MeSH$$aPrognosis
000274050 650_2 $$2MeSH$$aAged, 80 and over
000274050 650_2 $$2MeSH$$aGlial Fibrillary Acidic Protein: blood
000274050 650_2 $$2MeSH$$aNeurofilament Proteins: blood
000274050 650_2 $$2MeSH$$aMiddle Aged
000274050 650_2 $$2MeSH$$aNeuroglia
000274050 650_2 $$2MeSH$$aNeurons: pathology
000274050 650_2 $$2MeSH$$aSynapses
000274050 7001_ $$00000-0002-5893-1196$$aVollmuth, Christoph$$b1
000274050 7001_ $$0P:(DE-2719)9002026$$aHalbgebauer, Steffen$$b2$$udzne
000274050 7001_ $$aUngethüm, Kathrin$$b3
000274050 7001_ $$aHametner, Christian$$b4
000274050 7001_ $$aEssig, Fabian$$b5
000274050 7001_ $$aKollikowski, Alexander M$$b6
000274050 7001_ $$00000-0003-1295-2685$$aPham, Mirko$$b7
000274050 7001_ $$aSchuhmann, Michael K$$b8
000274050 7001_ $$aHeuschmann, Peter U$$b9
000274050 7001_ $$0P:(DE-2719)9001560$$aOeckl, Patrick$$b10$$udzne
000274050 7001_ $$aSteinacker, Petra$$b11
000274050 7001_ $$aRomoli, Michele$$b12
000274050 7001_ $$aD'Anna, Lucio$$b13
000274050 7001_ $$00000-0003-0631-8506$$aAbu-Rumeileh, Samir$$b14
000274050 7001_ $$aHaeusler, Karl Georg$$b15
000274050 7001_ $$aStoll, Guido$$b16
000274050 7001_ $$aNeugebauer, Hermann$$b17
000274050 7001_ $$00000-0003-4273-4267$$aOtto, Markus$$b18
000274050 773__ $$0PERI:(DE-600)2020241-6$$a10.1111/ene.16581$$gVol. 32, no. 1, p. e16581$$n1$$pe16581$$tEuropean journal of neurology$$v32$$x1351-5101$$y2025
000274050 8564_ $$uhttps://pub.dzne.de/record/274050/files/DZNE-2025-00031%20SUP.docx
000274050 8564_ $$uhttps://pub.dzne.de/record/274050/files/DZNE-2025-00031.pdf$$yOpenAccess
000274050 8564_ $$uhttps://pub.dzne.de/record/274050/files/DZNE-2025-00031%20SUP.doc
000274050 8564_ $$uhttps://pub.dzne.de/record/274050/files/DZNE-2025-00031%20SUP.odt
000274050 8564_ $$uhttps://pub.dzne.de/record/274050/files/DZNE-2025-00031%20SUP.pdf
000274050 8564_ $$uhttps://pub.dzne.de/record/274050/files/DZNE-2025-00031.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000274050 909CO $$ooai:pub.dzne.de:274050$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000274050 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002026$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000274050 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001560$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000274050 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000274050 9141_ $$y2025
000274050 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-22
000274050 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-22
000274050 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-22
000274050 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-22
000274050 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-22
000274050 915__ $$0LIC:(DE-HGF)CCBYNCND4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
000274050 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NEUROL : 2022$$d2023-10-22
000274050 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2023-10-22$$wger
000274050 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-22
000274050 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-22
000274050 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000274050 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-22
000274050 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NEUROL : 2022$$d2023-10-22
000274050 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-22
000274050 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-22
000274050 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-22
000274050 9201_ $$0I:(DE-2719)5000077$$kClinical Study Center (Ulm)$$lClinical Study Center (Ulm)$$x0
000274050 9201_ $$0I:(DE-2719)5000073$$kAG Öckl$$lTranslational Mass Spectrometry and Biomarker Research$$x1
000274050 980__ $$ajournal
000274050 980__ $$aVDB
000274050 980__ $$aUNRESTRICTED
000274050 980__ $$aI:(DE-2719)5000077
000274050 980__ $$aI:(DE-2719)5000073
000274050 9801_ $$aFullTexts